<DOC>
	<DOCNO>NCT02506179</DOCNO>
	<brief_summary>To evaluate real-life effect adalimumab psychological distress/depression symptom moderate-to-severe Ulcerative Colitis ( UC ) patient</brief_summary>
	<brief_title>Impact Adalimumab Patient-reported Outcomes Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patient must voluntarily sign date patient authorization . Patient must ≥ 18 year age . Patient must confirm diagnosis UC . Patient must : ) moderate severe UC ( Mayo endoscopic sub score 2 3 ) endoscopic investigation previous 3months close baseline visit b ) Mayo rectal bleeding subscore ≥ 2 calprotectine value great 250 µg/gr . Patient must previously treat conventional therapy include corticosteroid , azathioprine and/or 6mercaptopurine ( 6MP ) , inadequate response intolerant therapy . Patient must prescribe adalimumab part treatment treat physician . Patient previously receive adalimumab another anti tumor necrosis factor alpha ( TNFα ) biologic therapy , include limited Remicade ( infliximab ) , Simponi ( golimumab ) , Tysabri ( natalizumab ) , Entyvio ( vedolizumab ) . Patient history subtotal colectomy ileorectostomy colectomy ileoanal pouch , Kock pouch , ileostomy UC plan bowel surgery . Patient current diagnosis indeterminate colitis , ulcerative proctitis , current diagnosis and/or history Crohn 's disease . Patient tumor necrosis factor ( TNF ) immunemodulated disease . Patient significant history renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , cardiovascular , hepatic disease opinion investigator would adversely affect his/her participate study . A female patient pregnant breastfeeding . Patient currently participate another prospective study include control clinical trial observational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Moderate severe ulcerative colitis ( UC )</keyword>
	<keyword>Real-life effect</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Ulcerative colitis ( UC )</keyword>
	<keyword>Patient report outcome ( PRO )</keyword>
</DOC>